Patrick Harrington

Haematologist and researcher based in London. Interests in myeloid neoplasms, immunohaematology and the Arsenal.

[Patrick Harrington @drpharrington]

Very pleased to share our work on development of natural language processing pipeline to assess cardiovascular risk and thrombotic complications in MPN. Machine learning approach allowing assessment of health records of >900 patients and >23000 documents

https://t.co/ng7EMbYdYp

[Andrea Duminuco @ADuminuco]

Proud to share our recent study published on Leukaemia.

QRISK3 score can identify MPN patients with higher risk of TE based on CV risk factors that may benefit of early cytoreduction

https://t.co/AEwSikSEcz

@drpharrington @harrisoncn1

[Arsenal @Arsenal]

The kids are alright.

[Patrick Harrington @drpharrington]

Huge potential for future utilisation of NLP in research and healthcare setting @harrisoncn1 @KordastiL @PriyaSriRajah @DeeptiRadia @MPNVoice @G_ICEMD

[Patrick Harrington @drpharrington]

Very pleased to share our work on development of natural language processing pipeline to assess cardiovascular risk and thrombotic complications in MPN. Machine learning approach allowing assessment of health records of >900 patients and >23000 documents

https://t.co/ng7EMbYdYp

[Patrick Harrington @drpharrington]

Analysis highlighted increased thrombotic risk in PV patients compared with ET and identified hypertension as comorbidity of particular significance for VTE and CVA. Excellent work from @ADuminuco and Josh Au Yeung on getting this project completed.

[Patrick Harrington @drpharrington]

@PriyaSriRajah @G_ICEMD @SKordasti @harrisoncn1 @FangThaw @nat_curto @jm_osullivan Well done 👏

[Patrick Harrington @drpharrington]

- STAT5 inhibition by dasatinib dependent on reduction in IL-2

- TIM3+ cells show increase TCR signalling in pts on other TKI 2/3

Thanks to support from @dr_de_Lavallade @DillonHaem @DeeptiRadia @DrLornan @SKordasti @harrisoncn1 and all participating patients and families 3/3

[Patrick Harrington @drpharrington]

Out now in @Haematologica our paper on effects of TKIs on T cell signalling in patients with chronic myeloid leukaemia.

https://t.co/buDqCbjZ3Q

Dasatinib inhibits TCR and STAT5 signalling and inhibits T cell effector function cf. other TKIs. 1/3

[Patrick Harrington @drpharrington]

- immunostimulatory effects of dasatinib potentially explained by preferential inhibition of Treg TCR signalling cf effector cells

- pts with clonal CD8+ lymphocytosis also show greater inhibition of Treg signalling, may explain improved leukaemia related outcomes in this group

[Patrick Harrington @drpharrington]

https://t.co/aXazW1yI4m

Finally in print @BloodAdvances, data showing importance of third dose of vaccine for Omicron variant neutralisation as well as increased T cell response against Covid-19 in patients with #MPNsm and #CMLsm

[Patrick Harrington @drpharrington]

@arsenalkitgeek @koma_AFC You can have my ticket for Thursday if you are still here

[Sue Robinson @DrSue75]

Blood transfusion clinical fellow required to join the team ⁦@KHPHaematology⁩ ⁦@GSTTnhs⁩ ⁦@KingsCollegeNHS⁩ to look at data driven transfusion practice in partnership with the ⁦@DataDrivenBTRU⁩ team https://t.co/JaFkeEis8o

[Patrick Harrington @drpharrington]

Increased immune checkpoint expression also seen in patients with refractory disease. Significant increase in plasma pro-inflammatory cytokines at diagnosis. Likely due to LAA overload with increased disease burden. Potential future role for checkpoint inhibitor therapy? 2/2

[Patrick Harrington @drpharrington]

Paper out in BJHaem @BritSocHaem @G_ICEMD Patients with CML at diagnosis have increased frequency of effector Tregs and Tregs as well as increased expression of T cell exhaustion markers including TIM-3 and LAG-3 https://t.co/Hb43VEwDCU

[Patrick Harrington @drpharrington]

Many thanks to all patients who have participated in our study and to @bloodcancer_uk @BloodCancer_Res @MPNVoice for support

Updated results from study due shortly… #MPNsm #CMLsm

[Patrick Harrington @drpharrington]

Pleased to share our research recently published in @BloodCancerJnl highlighting impaired cellular and humoral response to SARS-CoV-2 vaccination in patients treated with ruxolitinib amongst cohort of MPN/CML pts

https://t.co/9P8Mp9zWe3

@dr_de_Lavallade @harrisoncn1 @G_ICEMD

[Patrick Harrington @drpharrington]

Other key findings include reduced response in patients receiving ChAdOx-1 vaccine after 2 doses. Presence of comorbidities also associated with reduced antibody response on multivariate analysis.

[Blood Journals Portfolio @BloodPortfolio]

Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis https://t.co/7wqghCgBjS

[Eric Topol @EricTopol]

A 2nd report today from @ljiresearch also demonstrates vaccination induced T-cells vs Omicron (B.1.1,519) well preserved compared with all variants and with 3 different vaccines
https://t.co/u9chjMohFs @aetarke @SetteLab

[GUY'S MYELOID CENTRE @G_ICEMD]

Many congratulations to @DeeptiRadia and all international colleagues on this pivotal paper: Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Fantastic game changing work! #Mastocytosis #MPNsm

https://t.co/M4bq6Qwn0d